American Association for Cancer Research

SHERPA: Unknown

People

  1. Solit
    Solit
  2. Ladanyi
    Ladanyi
  3. Rosen
    Rosen
  4. Hudis
    Hudis
  5. Scher
    Scher
  6. Berger
    Berger
  7. Baselga
    Baselga
  8. Reis-Filho
    Reis-Filho
  9. Cordon-Cardo
    Cordon-Cardo
  10. Schultz
    Schultz

Groups

  1. Department of Medicine (2074)
  2. Solid Tumor Oncology Division (1737)
  3. GSK Faculty (1623)
  4. Sloan Kettering Institute Faculty (794)
  5. Sloan Kettering Institute Postdocs (766)
  6. Department of Pathology and Laboratory Medicine (714)
  7. Human Oncology and Pathogenesis Program (677)
  8. Surgery (639)
  9. Breast Medicine Service (605)
  10. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (570)
Search Within
Formats
  1. Meeting Abstract (1996)
  2. Journal Article (1965)
  3. Editorial (41)
  4. Review (22)
  5. Conference Paper (14)
  6. Correspondence (4)
  7. Miscellaneous (4)
  8. Guidelines (1)
Groups
  1. Department of Medicine (2074)
  2. Solid Tumor Oncology Division (1737)
  3. GSK Faculty (1623)
  4. Sloan Kettering Institute Faculty (794)
  5. Sloan Kettering Institute Postdocs (766)
  6. Department of Pathology and Laboratory Medicine (714)

More Groups

People
  1. David Solit (174)
  2. Marc Ladanyi (157)
  3. Neal Rosen (141)
  4. Clifford Hudis (140)
  5. Howard Scher (139)
  6. Jose Baselga (138)

More People

Years
  1. 2025 (5)
  2. 2024 (55)
  3. 2023 (63)
  4. 2022 (261)
  5. 2021 (233)
  6. 2020 (271)

More Years

Publications
  1. Cancer Research (2685)
  2. Clinical Cancer Research (1362)

Results (4047)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Higher levels of circulating exhausted T-cells at pre- and post-infusion negatively associated with clinical efficacy in tisagenlecleucel (Tisa-cel) treated relapsed/refractory large B-cell lymphoma (r/r LBCL) patients (pts) in JULIET trial
    Meeting Abstract

    Jäger, U.; Han, X.; Germano, D.; Quinn, D.; Gaddis, D.; Masood, A.; Mulvey, T.; Mataraza, J.; Bishop, M. R.; Salles, G.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer
    Meeting Abstract

    Naing, A.; Callahan, M.; Costello, B. A.; Curti, B.; Hall, E.; Hansen, A.; Long, G. V.; Joshua, A. M.; Wetmore, C.; Weickhardt, A.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • A phase 1a/1b study of STK-012, an α/β IL-2 receptor selective partial agonist as monotherapy and in combination with pembrolizumab in advanced solid tumors (NCT05098132)
    Meeting Abstract

    Spigel, D.; Spira, A.; Zamarin, D.; McDermott, D. F.; Luke, J.; Heymach, J. V.; Previs, R.; Sullivan, R.; Gandhi, L.; Azrilevich, A.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Amcenestrant, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/HER2-advanced breast cancer (aBC): Combined biomarker analyses from a phase 1/2 study in postmenopausal women and a phase 1 study in postmenopausal Japanese women
    Meeting Abstract

    Iwata, H.; Bardia, A.; Lord, S.; Linden, H. M.; Campone, M.; Tamura, K.; Yonemori, K.; Mukohara, T.; Combeau, C.; Ternes, N.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • A phase I, open-label, dose-escalation study investigating a low-density lipoprotein receptor-related protein (LRP) 5/6 inhibitor, BI 905677, in patients with advanced solid tumors
    Meeting Abstract

    Élez, E.; Lenz, H. J.; de Jonge, M.; Yaeger, R.; Doi, T.; Pronk, L.; Teufel, M.; Marzin, K.; Tabernero, J.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer (NSCLC)
    Meeting Abstract

    de Rodas Gregorio, M. L.; Nagineni, V.; Ravi, A.; Datar, I. J.; Mino-Kenudson, M.; Corredor, G.; Barrera, C.; Behlman, L.; Rimm, D. L.; Herbst, R. S.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • First-in-human study of MEDI1191 (mRNA encoding IL-12) plus durvalumab in patients (pts) with advanced solid tumors
    Meeting Abstract

    Carneiro, B. A.; Zamarin, D.; Marron, T.; Mehmi, I.; Patel, S. P.; Subbiah, V.; El-Khoueiry, A.; Grand, D.; Garcia-Reyes, K.; Goel, S.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Epigenetic dysregulation from chromosomal transit in micronuclei
    Meeting Abstract

    Agustinus, A. S.; Raviram, R.; Dameracharla, B.; Luebeck, J.; Stransky, S.; Scipioni, L.; Myers, R. M.; Di Bona, M.; Duran, M.; Weigelt, B.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • A phase I dose escalation study of a tegavivint (BC2059) a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumors
    Meeting Abstract

    Cranmer, L.; Razak, A. A.; Ratan, R.; Choy, E.; George, S.; Liebner, D.; Stenehjem, D.; Gounder, M.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Fanconi anemia pathway deficiency drives copy number variation in squamous cell carcinoma
    Meeting Abstract

    Webster, A. L.; Sanders, M. A.; Patel, K.; Dietrich, R.; Noonan, R. J.; Lach, F. P.; White, R. R.; Goldfarb, A. M.; Hadi, K.; Edwards, M. M.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: